Scientific Advisory Board (SAB) includes experts in the development and approved T-cell engager therapies, supporting CAPTN-3’s advancement ...

Early-line data appears encouraging, with MajesTEC-3 complemented by emerging newly diagnosed data showing near-universal ...

Calidi Biotherapeutics, Inc. (NYSE American: CLDI) (“Calidi” or the “Company”), a biotechnology company pioneering the development of targeted genetic medicines, presented new data at the American ...

Rising incidence rates and innovation in immunotherapy drive an 8.66% CAGR from 2026 to 2035.Austin, United States, April 23, 2026 (GLOBE NEWSWIRE) -- According to SNS Insider, The T-cell Lymphoma ...

Researchers have engineered a synthetic Notch receptor system to directly label and profile cells interacting with developing T cells in the thymus. The study identified a broad network of immune and ...

Overall, TherVacB was found to be safe, well-tolerated, and highly immunogenic among the healthy study participants.

Nektar Therapeutics stock is upgraded from 'Buy' to 'Strong Buy' following robust phase 2b data for REZPEG in atopic ...

Preclinical data showed enhanced anti-tumor activity and reduced cytokine release compared to conventional single-chain CAR T approaches -- Early clinical case from CELESTIAL-301 trial, the ...

By Christopher J. Schaber, chairman, president, and CEO, Soligenix; published via Clinical Leader Soligenix (NASDAQ: ...

Recently, artificial intelligence (AI ) company OpenProtein.AI announced its partnership with large pharmaceutical ...

Soligenix (NASDAQ: SNGX) is emphasizing the strategic importance of patient-centric drug development, as outlined by CEO ...

Janos L. Tanyi, MD, PhD, of Penn Medicine, shared an early report of a new type of CAR T cell therapy, called KIR-CAR, in a Clinical Trial Plenary session at the AACR Annual Meeting 2026.